drugset / Trial / NCT00068029

Pegvisomant And Sandostatin LAR Combination Study

NCT00068029

Phase 4 Completed 75 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.

Timeline

Start
2003-10
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide
Subject Pegvisomant Protein / enzyme biologic

Indications